OFFICINA

Officina is a London-based synthetic biology company specializing in the development of novel RNA therapeutics, with a primary focus on transfer RNA (tRNA) engineering. Founded by experts from the Oxford/AstraZeneca vaccine team, the company utilizes a proprietary platform to design and optimize tRNAs that can suppress premature stop codons or modulate protein synthesis. This technology offers a potential treatment for a wide range of genetic disorders caused by nonsense mutations, as well as applications in oncology. By combining computational design with high-throughput screening, Officina aims to create a new class of precision medicines that address the root causes of disease at the translational level. The firm's approach seeks to overcome the limitations of traditional gene replacement by fixing the protein production process directly.